Company news

Immuron Limited news in 2017

Immuron Limited's news releases, calls and decks from 2017, newest first.

View company

Immuron Granted US Patent for NASH Treatment

November 13, 2017

Immuron Successfully Completes NASH Phase II Clinical Study

November 8, 2017

Travelan Experiences Strong Q1 FY2018 Sales Growth

November 7, 2017

Appendix 4E Preliminary Final Report (30 June 2017)

August 31, 2017

Immuron Opens Clinical Site to Commence C.Diff CDI Study

August 28, 2017

Immuron Approved to Commence Clinical Study in C.Difficile

August 9, 2017

Immuron to Present C.difficile Data at ClostPath 2017 Confer

August 8, 2017

Immuron Announces Management Changes

August 3, 2017

Success of NASH Phase II Interim Analysis Explained Further

July 13, 2017

NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes

July 10, 2017

Pre-Clinical C. difficile Infection Results Paper Published

July 3, 2017

IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M

June 9, 2017

Travelan Increases Industry Presence - Conf & Sales Update

June 2, 2017

Immuron Secures $1.5M R&D Cash Advance Loan Funding

June 1, 2017

NASDAQ Listing on Hold Pending NASH Interim Analysis Results

May 31, 2017

IMC Expands Agreement with US Army-3 Additional Therapeutics

May 16, 2017

Completion of Manufacturing of Drug Product for C-Diff Trial

May 10, 2017

IMC Form F1 - US Registration Statement (Prelim. Prospectus)

May 9, 2017

Positive Results of IMM-124E in Acute Colitis Studies

April 18, 2017

Close of Recruitment of Phase II NASH Trial

April 6, 2017

Appendix 4D - Half Year Report and Accounts - Dec 2016

February 28, 2017

Immuron Completes Phase II NASH Clinical Trial Recruitment

February 20, 2017

First Patient in Pediatric Fatty-Liver Phase II Trial

February 6, 2017

NASH MOA Study commences with SanyalBio & Duke University

January 19, 2017

Decks in 2017